Whole Genome Sequencing (ChromoSeq®) for Acute Lymphoblastic Leukemia (ALL) Patients
Part of paid clinical trials in St Louis, Missouri.
- Sponsor
- Washington University School of Medicine
- Study ID
- NCT07313592
- Status
- Recruiting
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- N/A - 30 Years
- Healthy Volunteers
- Not accepted
Study Details
This is a prospective data collection study evaluating the feasibility of using the ChromoSeq® assay for upfront classification in a real-time clinical setting of pediatric and young patients suspected of having ALL. Sixty patients will undergo collections of bone marrow and/or peripheral blood for the ChromoSeq® assay at time of initial workup as part of standard of care, and the patients will then be followed for clinical outcomes for up to 65 months.
Key Dates
- First listed
- Jan 2, 2026
- Start date
- Jun 3, 2026
- Status verified
- Oct 2026
- Primary completion
- Jul 15, 2028
- Completion
- Jul 15, 2028
Study Design
- Enrollment
- 60 participants (estimated)
Arms
- Arm: Child and Young Adult acute lymphoid leukemia (ALL) patientsData collection will include patient and disease related characteristics such as demographic information, relevant medical history, ALL classification, diagnosis information, treatment, treatment response, recurrence data, and transplant data. Specific clinical data points collected will include ChromoSeq® testing results, minimal residual disease testing results at 8 days into treatment, end of induction (28 days into treatment) and end of consolidation if applicable (\~3 months into treatment), and time of any relapses from time of diagnosis.
Primary Outcome Measure
Rate of success of ChromoSeq® [ Time Frame: Time of specimen collection to completion of results (total estimated time is 15 days) ]
Central Contacts
- Margaret Ferris, MD, PhD314-454-6018
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Washington University School of Medicine/St. Louis Children's Hospital | St Louis | Missouri | 63110 | Margaret Ferris, MD, PhD (PRINCIPAL_INVESTIGATOR) Feng Gao, PhD (SUB_INVESTIGATOR) |
Find similar trials in St Louis, MO
By condition
By specialty
Related Studies
- A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 MutationPHASE1/PHASE2 · Recruiting · Syndax Pharmaceuticals · Aurora, Colorado
- The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group StudyPHASE1/PHASE2 · Recruiting · PedAL BCU, LLC · Birmingham, Alabama
- Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer DetectionRecruiting · Alliance for Clinical Trials in Oncology · Anchorage, Alaska
- Biology Studies of Hematologic CancersEnrolling By Invitation · National Cancer Institute (NCI) · Bethesda, Maryland